COVID‑19 Alert: Stay home if you feel unwell. If you have a fever, cough and difficulty breathing, seek medical attention. Follow the directions of your local health authority. Source WHO

We have a lockdown, "Working from HOME" Please reach out for any queries at: help@alliedmarketresearch.com & Int'l : +1-503-894-6022, (UK) : +44-845-528-1300

Global Premenstrual Syndrome Treatment Market Expected to Reach $1,516 Million by 2026


quote The growth of the premenstrual syndrome market is attributed to rise in prevalence of PMS disorders across the globe. Furthermore, growing treatment awareness and rising adoption of premenstrual syndrome treatment are some other factors that contribute to the growth of the market. quote

Onkar Sumant
Manager, Healthcare at Allied Market Research

Get 20% Free Customization In This Report
Follow us on Social Media:       

According to a new report published by Allied Market Research, titled, "Premenstrual Syndrome Treatment Market, by Drug Type, Type and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019–2026," the global premenstrual syndrome treatment market size was valued at $1,129  million in 2018, and is projected to reach $1,516   million by 2026, growing at a CAGR of 3.7% from 2019 to 2026. 

Premenstrual syndrome (PMS) is a condition that affects emotional behavior and physical health of women during or few days before their menstrual cycle. PMS often leads to acne, tender breasts, bloating, irritability, and mood swings , which could be managed by lifestyle changes or drug treatment. Medication such as analgesics, antidepressants, oral contraceptives and ovarian suppression agents are generally used to manage PMS. 

The premenstrual syndrome treatment market is expected to experience a significant growth during the forecast period, owing to rise in demand for PMS treatment medication across the globe and increase in awareness related to PMS. Surge in number of target population is further anticipated to boost the premenstrual syndrome treatment market growth during the forecast period. According to the American Psychiatric Association, almost 90% of women of child bearing age experience premenstrual symptoms. In addition, growth in demand for premenstrual therapeutics in developing countries  further creates opportunities for the premenstrual syndrome treatment market. However, unknown etiology and pathophysiology of PMS and adverse effects associated with off label drugs are anticipated to hamper the market growth. 

By drug type, the market is categorized into analgesics, antidepressants, oral contraceptives & ovarian suppression agents, and others. Presently, analgesics is the major revenue contributing segment and is estimated to show the same dominance during the forecast period, owing to preferable use of Nonsteroidal anti-inflammatory (NSAIDs) as first line treatment in management of PMS. 

According to distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. The online providers segment is anticipated to depict significant growth during the forecast period, due to rise in preference for online purchasing of drugs, increase in awareness of online pharmacies, and rise in number of internet users.

Key Findings of the Study:

  • By drug Type, the analgesics segment held more than three forth share in the global market in 2018. 
  • By distribution channel, the online providers segment exhibits fastest growth and is expected to grow at a CAGR of 4.9% from 2019 to 2026.  
  • By distribution channel, the drug stores & retail pharmacies segment held the largest market share in 2018, and is expected to remain dominant throughout the forecast period.  
  • Region wise, Asia-Pacific is expected to experience a significant growth, registering a CAGR of 5.1% during the forecast period. 

North America accounted for approximately one-half of the global premenstrual syndrome treatment market share in 2018, and is expected to remain dominant throughout the forecast period. This was attributed to the rise in higher adoption of premenstrual syndrome treatment medication, rise in PMS treatment awareness among patients, and large number of target population, with wide availability of PMS treatment therapeutics in this region. However, Asia-Pacific is expected to experience the highest growth rate during the forecast period, majorly due to growing number of target population with increase in adoption of premenstrual syndrome treatment medication in the region. 

Need More Information

pr-det-talk Talk to David (Europe)

pr-det-talk Talk to Sona Padman (Americas)

5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States

pr-det-phone Toll Free: +1-800-792-5285

pr-det-phone UK: +44-845-528-1300

pr-det-phone Hong Kong: +852-301-84916

pr-det-phone India (Pune): +91 2066346060

pr-det-phone Fax: +1(855) 550-5975

pr-det-phone help@alliedmarketresearch.com


For Media Inquiries, Please Contact

Ram D
Communications Officer
Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at


First time buyer?
Check offers and discount on this report
To get this report

Click Here

quote Premenstrual Syndrome Treatment Market by Drug Type (Analgesics, Antidepressants, Oral Contraceptives & Ovarian Suppression Agents, and Others), Type (Prescription and OTC), and Distribution Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, Online Providers): Global Opportunity Analysis and Industry Forecast, 2019–2026 quote

View Report

Why Allied Market Research?


Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time of readers


Featured Readings


Get Fresh content delivered

Get insights on topics that matter to your business. Stay updated on the area that interests you.

Get Industry Data Alerts

Buy Full Version
"Global Premenstrual Syndrome Treatment Market"
Purchase Enquiry